Article citationsMore>>

Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F. and Reindl, M. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. New England Journal of Medicine, 349, 139-145. doi:10.1056/NEJMoa022328

has been cited by the following article:

• TITLE: Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression

  AUTHORS: Dmitry Kostyushev, Ivan Tsarev, Dmitry Gnatenko, Mikhail Paltsev, Sergey Suchkov

  KEYWORDS: Multiple Sclerosis; Antibodies; Autoimmunity; Pre-Clinical Diagnosis; Diagnosis; Prediction; Proteomics

  JOURNAL NAME: Open Journal of Immunology, Vol.1 No.3, December 31, 2011

  ABSTRACT: MS is a severe progressive autoimmune disease with slight short-term relapses in its course. Autoagression against vulnerable myelin-associated Ags results in multiple lesions throughout the CNS. Abnormal responses against nervous issues are mainly affected by cell-mediated and humoral immunity. The first one plays a key role in the restructuring of myelin, while the last one is a biomarker of MS and does not participate in the gradation of the disease. Wide-scale autoimmune attack towards nervous tissues leads to a stepwise demyelination with concomitant release of myelin Ags (epitope spreading), formation of Abs and, consequently, systematization of pro-inflammatory responses. Monitoring of antimyelin-antibodies (Abs: OSP, MOBP, BMP, MOG, PLP) in peripheral blood and cerebrospinal fluid (CSF) is just a brick for making the preclinical diagnosis of MS and timely implementation of predictive measures and preventive treatment. Major autoAbs and their target antigens are discussed in this chapter with a special emphasize on the possibility of their impact for identification of pre-morbid stages and differential diagnosis of MS.